Ink and Echo | 墨響 | The Evolving Journal

Michigan ADRC: A Collaborative Leader in Alzheimer’s Disease Research (Updated March 2026) Original Post Date: July 13, 2025 | Updated: March 2026 Michigan Alzheimer’s Disease Research Center (Michigan ADRC / MADC) The Michigan Alzheimer’s Disease Research Center (Michigan ADRC), part of the national network of NIH-funded Alzheimer’s Disease Research Centers, stands out for its statewide collaboration among the University of Michigan (U-M), Michigan State University (MSU), and Wayne State University (WSU). This unique partnership creates a comprehensive resource for researchers, clinicians, trainees, and the public across Michigan, with a strong emphasis on Alzheimer’s disease and related dementias (ADRD)—including Lewy body dementia and vascular contributions—while prioritizing non-amyloid pathways , accessible biomarkers, neuroimaging, diversity, and community engagement. Key Cores and Programs (building on the original strengths): University of Michigan Memory and Aging Projec...

  For many years, I’ve been listening to   The Dementia Matters   podcast by Dr. Nathaniel Chin. What strikes me most is not only his dedication to advancing dementia care and research but also his genuine compassion, clarity, and commitment to empowering patients, families, and caregivers through education and understanding. The podcast ultimately led me to the University of Wisconsin Alzheimer’s Disease Research Center, where I have learned so much about their ongoing developments, accomplishments, and the promising progress being made—both in the near and distant future—toward finding a cure for this devastating disease. It has long been my commitment to support and donate to research institutions like this until a cure for Alzheimer’s is found. We are racing against time, and I remain hopeful that in the coming years we will be able to pinpoint the root cause and achieve a true cure for this disease. The following is a briefing for Dr. Chin and UW-ADRC. Dr. Nathaniel ...

  A Warning Hidden in Plain Sight Evaluating the Risks of Inexperienced Financial Leadership in E-commerce Preface This paper did not begin as a research project. It began as a conversation — two separate conversations, actually — with friends who happened to work at the same e-commerce company. Their accounts, shared independently, were remarkably consistent: a profitable organization brought low not by market forces or bad luck, but by a pattern of poor financial leadership and, critically, by a broader culture of institutional self-interest that enabled it. What emerged from those conversations was more complicated than a single bad actor. Yes, the CFO — credentialed and outwardly legitimate — had previously guided a company into bankruptcy and simply moved into an identical role within the same industry without any period of reflection or accountability. But the failure did not rest on one person's shoulders alone. What was equally troubling was that department managers — acros...

  Recent Advances in Biomarker Research for Alzheimer’s Disease: Clinical Utility, Progress, and Racial/Ethnic Disparities Abstract Alzheimer’s disease (AD) biomarkers have undergone a transformative shift from invasive cerebrospinal fluid (CSF) and expensive imaging to accessible blood-based assays. This paper synthesizes recent findings from community-based cohorts, clinical trial registries, and primary care studies to evaluate the progress of biomarker research. Key markers such as phosphorylated tau (p-tau) isoforms, neurofilament light chain (NfL), and glial fibrillary acidic protein (GFAP) demonstrate high prognostic and diagnostic accuracy. Furthermore, we examine the critical issue of racial and ethnic disparities in AD progression, biomarker expression, and treatment access, with a specific focus on recent breakthroughs in Asian populations. While blood biomarkers show promise for universal application, significant gaps remain in ensuring equitable diagnosis and care acro...